Clearmind Medicine Files US Patent for Psychedelic Eating Disorder Treatment
Ticker: CMND · Form: 6-K · Filed: Apr 10, 2024 · CIK: 1892500
| Field | Detail |
|---|---|
| Company | Clearmind Medicine INC. (CMND) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent-filing, psychedelics, healthcare, mental-health
TL;DR
Clearmind files US patent for psychedelic eating disorder treatment, CMND-100.
AI Summary
Clearmind Medicine Inc. announced on April 10, 2024, that it has filed a U.S. patent application for a novel psychedelic-based treatment for eating disorders. This application covers the use of their proprietary compound, CMND-100, in combination with specific therapeutic protocols. The company aims to protect its intellectual property related to this innovative treatment approach.
Why It Matters
This patent filing is significant as it could provide Clearmind Medicine with exclusive rights to a new treatment for eating disorders, potentially opening up a new market for their psychedelic-based therapies.
Risk Assessment
Risk Level: medium — The company is in the early stages of patent application and clinical development, with no guarantee of patent approval or market success.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K report and applicant of the patent
- April 10, 2024 (date) — Date of the press release and filing
- CMND-100 (drug_candidate) — Proprietary compound for treating eating disorders
- U.S. Patent Application (legal_document) — Filed for psychedelic-based treatment
- Eating Disorders (medical_condition) — Target condition for the new treatment
FAQ
What is the specific nature of the U.S. patent application filed by Clearmind Medicine?
The patent application covers the use of Clearmind's proprietary compound, CMND-100, in combination with specific therapeutic protocols for the treatment of eating disorders.
When was the press release regarding the patent application issued?
The press release was issued on April 10, 2024.
What is the primary focus of Clearmind Medicine's research and development as indicated by this filing?
The filing indicates a focus on developing psychedelic-based treatments, specifically for eating disorders using their compound CMND-100.
Which SEC filing form is Clearmind Medicine using to report this information?
Clearmind Medicine is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Are Clearmind Medicine's Registration Statements on Form F-3 incorporated by reference?
Yes, the first and third paragraphs of the press release attached to this Form 6-K are incorporated by reference into the Registrant's Registration Statements on Form F-3 (File No. 333-275991).
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-04-10 16:00:20
Filing Documents
- ea0203631-6k_clearmind.htm (6-K) — 11KB
- ea020363102ex99-1_clearmind.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-031866.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: April 10, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3